In a retrospective cohort study of patients in the OneFlorida Clinical Research Consortium, 4.9% of 1376 patients taking CDK4/6 inhibitors developed AF and there was no difference in incidence among the different CDK4/6 inhibitors [40]. This evidence concerns the gene CDK4 and atrial fibrillation.